GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (FRA:9EN) » Definitions » Balance Sheet Cash And Cash Equivalents

Pharvaris NV (FRA:9EN) Balance Sheet Cash And Cash Equivalents


View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Balance Sheet Cash And Cash Equivalents?

Please go to this page to see Cash And Cash Equivalents for non-financial companies.


Pharvaris NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (FRA:9EN) » Definitions » Balance Sheet Cash And Cash Equivalents
Traded in Other Exchanges
Address
Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.